Sarepta Therapeutics, Inc. (SRPT)
18.13
-0.66
(-3.51%)
USD |
NASDAQ |
Aug 24, 16:00
18.13
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Enterprise Value : 2.242B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 2.242B |
| August 20, 2026 | 2.287B |
| August 19, 2026 | 2.341B |
| August 18, 2026 | 2.161B |
| August 17, 2026 | 2.178B |
| August 14, 2026 | 2.169B |
| August 13, 2026 | 2.203B |
| August 12, 2026 | 2.199B |
| August 11, 2026 | 2.182B |
| August 10, 2026 | 2.072B |
| August 07, 2026 | 2.030B |
| August 06, 2026 | 2.030B |
| August 05, 2026 | 1.940B |
| August 04, 2026 | 1.989B |
| August 03, 2026 | 1.935B |
| July 31, 2026 | 1.827B |
| July 30, 2026 | 1.901B |
| July 29, 2026 | 1.898B |
| July 28, 2026 | 1.887B |
| July 27, 2026 | 1.936B |
| July 24, 2026 | 1.914B |
| July 23, 2026 | 1.935B |
| July 22, 2026 | 1.928B |
| July 21, 2026 | 1.970B |
| July 20, 2026 | 2.035B |
| Date | Value |
|---|---|
| July 17, 2026 | 2.076B |
| July 16, 2026 | 2.077B |
| July 15, 2026 | 2.117B |
| July 14, 2026 | 2.154B |
| July 13, 2026 | 2.245B |
| July 10, 2026 | 2.259B |
| July 09, 2026 | 2.425B |
| July 08, 2026 | 2.392B |
| July 07, 2026 | 2.348B |
| July 06, 2026 | 2.283B |
| July 02, 2026 | 2.294B |
| July 01, 2026 | 2.180B |
| June 30, 2026 | 2.155B |
| June 29, 2026 | 2.180B |
| June 26, 2026 | 2.162B |
| June 25, 2026 | 2.075B |
| June 24, 2026 | 2.146B |
| June 23, 2026 | 2.206B |
| June 22, 2026 | 2.247B |
| June 18, 2026 | 2.234B |
| June 17, 2026 | 2.174B |
| June 16, 2026 | 2.049B |
| June 15, 2026 | 2.048B |
| June 12, 2026 | 2.000B |
| June 11, 2026 | 1.967B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Moderna, Inc. | 54.06B |
| ImmunityBio, Inc. | 9.076B |
| X4 Pharmaceuticals, Inc. | 256.98M |
| MapLight Therapeutics, Inc. | 206.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.89M |
| Revenue (Quarterly) | 401.25M |
| Total Expenses (Quarterly) | 406.14M |
| EPS Diluted (Quarterly) | -0.0464 |
| Gross Profit Margin (Quarterly) | 60.18% |
| Profit Margin (Quarterly) | -1.22% |
| Earnings Yield | -15.98% |
| Normalized Earnings Yield | -9.445 |